Literature DB >> 21296387

Male mice have increased thrombotic potential: sex differences in a mouse model of venous thrombosis.

Christine M Alvarado1, Jose A Diaz, Angela E Hawley, Shirley K Wrobleski, Robert E Sigler, Daniel D Myers.   

Abstract

INTRODUCTION: Our objectives were to characterize sex differences during venous thrombosis, using the electrolytic inferior vena cava model of the disease.
MATERIALS AND METHODS: Male and female C57BL/6 mice (6-8 weeks) underwent inferior vena cava thrombosis. Time points included 6 hours, day 2, day 6, and day 14 post surgery, along with surgically naïve true controls and surgical shams. Analyses included thrombus weight, vein wall morphometrics, vein wall protein and gene expression for P-selectin, interleukin-1β, and tumor necrosis factor-α; hematology, soluble P-selectin, and plasma microparticle tissue factor activity assays.
RESULTS: Male venous thrombi were significantly larger than females at days 2 (13.1 ± 1.0 vs. 6.8 ± 0.5 × 10(-3) grams, p < 0.01), 6 (10.4 ± 0.8 vs. 5.4 ± 0.5 × 10(-3) grams, p < 0.01) and 14 (6.3 ± 0.5 vs. 4.1 ± 0.3 × 10(-3) grams, p < 0.01). Both male and female mice exhibited significantly increased vein wall P-selectin at 6 hours, vs. true controls (p < 0.05). Males had increased vein wall interleukin-1β, versus females, at 6 hours (180.926 ± 24.596 vs. 60.417 ± 10.478 pg/mL, p < 0.05) and day 6 (76.966 ± 13.081 vs. 33.834 ± 4.198 pg/mL, p < 0.01). Males showed decreased tumor necrosis factor-α expression (-66 %) at 6 hours. Females had increased tumor necrosis factor-α expression at 6 hours (+541%) and day 6 (+539%). Both sexes demonstrated decreased peripheral platelets at 6 hours (p < 0.05), coinciding with thrombogenesis. Plasma P-selectin increased in both sexes, versus controls, through day 6 (p < 0.05).
CONCLUSIONS: Males had significantly larger venous thrombi than females. Sex differences in vascular anatomy and response to inflammation may influence thrombus formation in our mouse thrombosis model.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296387      PMCID: PMC3081977          DOI: 10.1016/j.thromres.2011.01.004

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  31 in total

1.  Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns.

Authors:  Joshua H Wong; Jonathan Dukes; Robert E Levy; Brandon Sos; Sara E Mason; Tina S Fong; Ethan J Weiss
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

Review 2.  Analysis of tissue factor positive microparticles.

Authors:  Nigel S Key
Journal:  Thromb Res       Date:  2010-02-26       Impact factor: 3.944

Review 3.  Factor VIIa and tissue factor--from cell biology to animal models.

Authors:  L Vijaya Mohan Rao; Nigel Mackman
Journal:  Thromb Res       Date:  2010-02-12       Impact factor: 3.944

4.  Sexual dimorphism in superantigen shock involves elevated TNF-alpha and TNF-alpha induced hepatic apoptosis.

Authors:  Lee Faulkner; Daniel M Altmann; Stephan Ellmerich; Ilpo Huhtaniemi; Gordon Stamp; Shiranee Sriskandan
Journal:  Am J Respir Crit Care Med       Date:  2007-06-15       Impact factor: 21.405

5.  Differences in clinical presentation of deep vein thrombosis in men and women.

Authors:  E Roseann Andreou; T Koru-Sengul; L Linkins; S M Bates; J S Ginsberg; C Kearon
Journal:  J Thromb Haemost       Date:  2008-07-28       Impact factor: 5.824

6.  Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice.

Authors:  J-G Wang; D Manly; D Kirchhofer; R Pawlinski; N Mackman
Journal:  J Thromb Haemost       Date:  2009-04-27       Impact factor: 5.824

Review 7.  Acute venous disease: venous thrombosis and venous trauma.

Authors:  Mark H Meissner; Thomas W Wakefield; Enrico Ascher; Joseph A Caprini; Anthony J Comerota; Bo Eklof; David L Gillespie; Lazar J Greenfield; Aiwu Ruth He; Peter K Henke; Anil Hingorani; Russell D Hull; Craig M Kessler; Robert D McBane; Robert McLafferty
Journal:  J Vasc Surg       Date:  2007-12       Impact factor: 4.268

Review 8.  Venous thromboembolism: risk factors for recurrence.

Authors:  Tienan Zhu; Isabelle Martinez; Joseph Emmerich
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03       Impact factor: 8.311

9.  Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor downregulation via suppression of nuclear factor-kappa B in endothelial cells.

Authors:  Hong Jin; Wen-Bing Qiu; Yi-Fang Mei; Dong-Ming Wang; Yu-Guang Li; Xue-Rui Tan
Journal:  Asian J Androl       Date:  2009-01-26       Impact factor: 3.285

Review 10.  Effects of race and ethnicity on the incidence of venous thromboembolism.

Authors:  Richard H White; Craig R Keenan
Journal:  Thromb Res       Date:  2009       Impact factor: 3.944

View more
  11 in total

1.  Effects of analgesic use on inflammation and hematology in a murine model of venous thrombosis.

Authors:  Gerald A Hish; Jose A Diaz; Angela E Hawley; Daniel D Myers; Patrick A Lester
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

2.  In vivo photoacoustic lipid imaging in mice using the second near-infrared window.

Authors:  Gurneet S Sangha; Evan H Phillips; Craig J Goergen
Journal:  Biomed Opt Express       Date:  2017-01-10       Impact factor: 3.732

Review 3.  Critical review of mouse models of venous thrombosis.

Authors:  Jose A Diaz; Andrea T Obi; Daniel D Myers; Shirley K Wrobleski; Peter K Henke; Nigel Mackman; Thomas W Wakefield
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03       Impact factor: 8.311

4.  Myeloid cell tissue factor does not contribute to venous thrombogenesis in an electrolytic injury model.

Authors:  Anna L Hampton; Jose A Diaz; Angela E Hawley; Shirley K Wrobleski; Jian-Guo Wang; Rebecca D Lee; Daniel Kirchhofer; Robert E Sigler; Thomas W Wakefield; Nigel Mackman; Daniel D Myers
Journal:  Thromb Res       Date:  2011-12-20       Impact factor: 3.944

5.  Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Magdalena L Bochenek; Christiane Leidinger; Nico S Rosinus; Rajinikanth Gogiraju; Stefan Guth; Lukas Hobohm; Kerstin Jurk; Eckhard Mayer; Thomas Münzel; Mareike Lankeit; Markus Bosmann; Stavros Konstantinides; Katrin Schäfer
Journal:  Circ Res       Date:  2019-11-21       Impact factor: 17.367

6.  Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis.

Authors:  Holly Payne; Alexander Brill
Journal:  J Vis Exp       Date:  2017-12-22       Impact factor: 1.355

7.  CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models.

Authors:  Piyushkumar R Kapopara; Nooshin S Safikhan; Jenny L Huang; Scott C Meixner; Kevin Gonzalez; Houra Loghmani; Wolfram Ruf; Alan E Mast; Victor Lei; Edward L G Pryzdial; Edward M Conway
Journal:  J Thromb Haemost       Date:  2021-05-07       Impact factor: 16.036

8.  Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease.

Authors:  Victor K Tso; Beate C Sydora; Rae R Foshaug; Thomas A Churchill; Jason Doyle; Carolyn M Slupsky; Richard N Fedorak
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

9.  SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis.

Authors:  Julia Tilburg; Daniëlle M Coenen; Gaia Zirka; Sophie Dólleman; Annemarie M van Oeveren-Rietdijk; Mieke F A Karel; Hetty C de Boer; Judith M E M Cosemans; Henri H Versteeg; Pierre E Morange; Bart J M van Vlijmen; Chrissta X Maracle; Grace M Thomas
Journal:  J Thromb Haemost       Date:  2020-05-15       Impact factor: 5.824

Review 10.  Understanding the Pathophysiology of Thrombotic APS through Animal Models.

Authors:  Alex A Gandhi; Shanea K Estes; Christine E Rysenga; Jason S Knight
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.